Ieq Capital LLC lifted its holdings in shares of Cerus Co. (NASDAQ:CERS – Free Report) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,169,487 shares of the biotechnology company’s stock after buying an additional 26,748 shares during the period. Ieq Capital LLC’s holdings in Cerus were worth $3,341,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in CERS. R Squared Ltd acquired a new stake in Cerus in the fourth quarter valued at about $29,000. Creative Planning lifted its position in Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 8,411 shares during the period. PCA Investment Advisory Services Inc. acquired a new stake in Cerus in the fourth quarter valued at about $46,000. Intech Investment Management LLC acquired a new stake in Cerus in the third quarter valued at about $71,000. Finally, SG Americas Securities LLC acquired a new stake in Cerus in the third quarter valued at about $121,000. Institutional investors and hedge funds own 78.37% of the company’s stock.
Cerus Trading Down 5.2 %
Shares of Cerus stock opened at $1.65 on Friday. Cerus Co. has a 12-month low of $1.38 and a 12-month high of $2.59. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. The stock has a market cap of $306.42 million, a PE ratio of -15.00 and a beta of 1.29. The company has a 50-day moving average of $1.74 and a two-hundred day moving average of $1.83.
Insider Buying and Selling at Cerus
In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.40% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price objective on shares of Cerus in a research report on Friday.
Get Our Latest Stock Analysis on Cerus
Cerus Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also
- Five stocks we like better than Cerus
- What Are Dividend Challengers?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- How to Use the MarketBeat Excel Dividend Calculator
- DuPont’s Electronics Spinoff: The Start of Something Big
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS – Free Report).
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.